Class I HDAC inhibitor (IC50 values are 0.18, 0.74, 44.9 and >100 μM for HDAC1, 3, 8 and 6, respectively). Exhibits antiproliferative effects and induces apoptosis in a range of tumor cell lines in vitro and in vivo. Increases estrogen receptor α- and aromatase expression in breast cancer cells. Inhibits PCB-induced neuronal cell death by preventing HDAC3 binding and histone deacetylation within the synapsin-1 promoter.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 376.41. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.66 mL||13.28 mL||26.57 mL|
|5 mM||0.53 mL||2.66 mL||5.31 mL|
|10 mM||0.27 mL||1.33 mL||2.66 mL|
|50 mM||0.05 mL||0.27 mL||0.53 mL|
References are publications that support the products' biological activity.
Saito et al (1999) A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc.Natl.Acad.Sci. 96 4592 PMID: 10200307
Beckers et al (2007) Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group. Int.J.Cancer 121 1138 PMID: 17455259
Formisano et al (2015) MS-275 inhibits aroclor 1254-induced SH-SY5Y neuronal cell toxicity by preventing the formation of the HDAC3/REST complex on the synapsin-1 promoter. J.Pharmacol.Exp.Ther. 352 236 PMID: 25467131
Sabnis et al (2011) Functional activation of the estrogen receptor-α and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole. Cancer Res. 71 1893 PMID: 21245100
If you know of a relevant reference for MS 275, please let us know.
View Related Products by Product Action
Keywords: MS 275, supplier, MS275, HDAC1, HDAC3, inhibits, inhibitors, class, I, histone, deacetylases, SNDX275, entinostat, SNDX, 275, Histone, Deacetylases, Histone, Deacetylases, Tocris Bioscience
Citations for MS 275
Citations are publications that use Tocris products.
Currently there are no citations for MS 275. Do you know of a great paper that uses MS 275 from Tocris? If so please let us know.
Reviews for MS 275
There are currently no reviews for this product. Be the first to review MS 275 and earn rewards!
Have you used MS 275?
Submit a review and receive an Amazon gift card.
$10US/$10CAN/€7/£6 gift card for a review without an image
$25US/$25CAN/€18/£15 gift card for a review with an image
*Offer only valid in the USA / Canada, UK and EuropeSubmit a Review
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Epigenetics Scientific Review
Written by Susanne Müller-Knapp and Peter J. Brown, this review gives an overview of the development of chemical probes for epigenetic targets, as well as the impact of these tool compounds being made available to the scientific community. In addition, their biological effects are also discussed. Epigenetic compounds available from Tocris are listed.
Epigenetics Research Bulletin
Produced by Tocris and updated in 2014, the epigenetics research bulletin gives an introduction into mechanisms of epigenetic regulation, and highlights key Tocris products for epigenetics targets including:
- DNA Methyltransferases
- Histone Deacetylases
- Histone Demethylases
- Histone Methyltransferases
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.